---
figid: PMC10378516__curroncol-30-00480-g001
figtitle: Strategic Insight into the Combination Therapies for Metastatic Colorectal
  Cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Danio rerio
- Homo sapiens
pmcid: PMC10378516
filename: curroncol-30-00480-g001.jpg
figlink: /pmc/articles/PMC10378516/figure/curroncol-30-00480-f001/
number: F1
caption: EGFR-MAPK signaling pathway and the targeted point by specific inhibitors.
  (A) Normal MAPK pathway. (B) HER2 amplification. HER2 forms homodimer or couples
  with heterodimeric partners, EGFR or HER3. (C) BRAF activating signaling. A triple
  combination with BRAF, MEK, and EGFR inhibition demonstrated significant clinical
  benefit. (D) KRAS activating signaling be specific mutation at G12C. The dual inhibition
  of KRASG12C and EGFR demonstrated a better response. The addition of SHP2 inhibition
  might overcome the resistance of the KRASG12C inhibitor.
papertitle: Strategic Insight into the Combination Therapies for Metastatic Colorectal
  Cancer.
reftext: Yoshihito Kano, et al. Curr Oncol. 2023 Jul;30(7):6546-6558.
year: '2023'
doi: 10.3390/curroncol30070480
journal_title: Current Oncology
journal_nlm_ta: Curr Oncol
publisher_name: MDPI
keywords: combination therapy | metastatic colorectal cancer | molecular targeted
  therapy | conversion surgery | liquid biopsy | RAS | KRASG12C
automl_pathway: 0.9488449
figid_alias: PMC10378516__F1
figtype: Figure
redirect_from: /figures/PMC10378516__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10378516__curroncol-30-00480-g001.html
  '@type': Dataset
  description: EGFR-MAPK signaling pathway and the targeted point by specific inhibitors.
    (A) Normal MAPK pathway. (B) HER2 amplification. HER2 forms homodimer or couples
    with heterodimeric partners, EGFR or HER3. (C) BRAF activating signaling. A triple
    combination with BRAF, MEK, and EGFR inhibition demonstrated significant clinical
    benefit. (D) KRAS activating signaling be specific mutation at G12C. The dual
    inhibition of KRASG12C and EGFR demonstrated a better response. The addition of
    SHP2 inhibition might overcome the resistance of the KRASG12C inhibitor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MKP-4
  - p38b
  - rl
  - csw
  - Egfr
  - Sos
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - Pdfr
  - ptpn11a
  - egfra
  - rab1ab
  - her2
  - braf
  - si:dkey-222f8.3
  - her3
  - kras
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - PTPN11
  - EGFR
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - ERBB2
  - EPHB2
  - ERBB3
  - OPN1MW
  - OPN1MW2
  - OPN1MW3
  - GDP
  - Tucatinib
  - Encorafenib
  - Vemurafenib
  - Binimetinib
  - Trametinib
  - TNO
---
